Shilpa Medicare signs long-term CDMO manufacturing deal with NXI Therapeutics
The partnership covers the entire product lifecycle from early-stage development through commercialization
The partnership covers the entire product lifecycle from early-stage development through commercialization
Globally, cervical cancer is the fourth most common cancer among women, with approximately 30,447 new cases diagnosed in Europe in 2020
Under the manufacturing agreement, Lonza will provide drug substance for Asher Bio's cis-targeted IL-2 fusion protein
Subscribe To Our Newsletter & Stay Updated